Literature DB >> 12658270

Antigen-induced regulatory T cells in autoimmunity.

Matthias G von Herrath1, Leonard C Harrison.   

Abstract

The ultimate goal of any treatment for autoimmune diseases is antigen- and/or site-specific suppression of pathology. Autoaggressive lymphocytes need to be eliminated or controlled to prevent tissue damage and halt the progression of clinical disease. Strong evidence is emerging that the induction of regulatory T (T(Reg)) cells by autoantigens can suppress disease, even if the primary, initiating autoantigens are unknown and if inflammation is progressive. An advantage of these autoreactive T(Reg) cells is their ability to act as bystander suppressors and dampen inflammation in a site-specific manner in response to cognate antigen expressed locally by affected tissues. In this review, we consider the nature and function of such antigen-specific T(Reg) cells, and strategies for their therapeutic induction are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658270     DOI: 10.1038/nri1029

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  80 in total

1.  Neutrophils sustain pathogenic CD8+ T cell responses in the heart.

Authors:  Nir Grabie; Dennis T Hsieh; Chiara Buono; Jason R Westrich; Jessica A Allen; Hong Pang; George Stavrakis; Andrew H Lichtman
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 2.  Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines.

Authors:  Reinhard Hohlfeld; Hartmut Wekerle
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-11       Impact factor: 11.205

3.  Identification of a unique double-negative regulatory T-cell population.

Authors:  Byung O Lee; Joyce E Jones; Cory J Peters; David Whitacre; Lars Frelin; Janice Hughes; Won-Keun Kim; David R Milich
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

Review 4.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

5.  Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.

Authors:  Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-26       Impact factor: 11.205

6.  Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge.

Authors:  Neil Taylor; Karen McConachie; Karen McConnachie; Claudia Calder; Rosemary Dawson; Andrew Dick; Jonathon D Sedgwick; Janet Liversidge
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 7.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

9.  Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.

Authors:  Yi-Ling Chen; Jung-Hua Fang; Ming-Derg Lai; Yan-Shen Shan
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

10.  LPS-treated bone marrow-derived dendritic cells induce immune tolerance through modulating differentiation of CD4+ regulatory T cell subpopulations mediated by 3G11 and CD127.

Authors:  Fang Zhou; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.